As excessive α-cell glucagon secretion is an important contributor to hyperglycemia during type 2 diabetes, the ability to lower glucagon secretion is one of the main therapeutic advantages of incretin-based therapy (45). The gene discussed is GCG; the disease is type 2 diabetes mellitus.